People In Brief

Merck names Frazier president: Merck, in an expected move, appoints the current head of its Global Human Health business, Ken Frazier, as president of the firm. Frazier moves to the spot after three years in the Global Human Health post and as Merck's general counsel for eight years prior to that, the firm said April 28. Adam Schechter, current U.S. head for Global Human Health, will succeed Frazier as global president. Current Merck President Dick Clark will remain as CEO and chairman; both Schecter and Frazier are seen as potential successors to Clark. Merck in February appointed former Johnson & Johnson executive Bridgette Heller as executive VP and president of its consumer health care division. Whitehouse Station, N.J.-based Merck acquired the division as part of its November 2009 merger with Schering-Plough (1"The Tan Sheet" Feb. 22, 2010)

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

Non-Submissions To UK HTA Body Could Increase Unless Commercial Environment Improves, Warns Industry

 
• By 

Finding ways to lower the rebates paid by the pharmaceutical industry to the UK government and fostering partnerships to make the UK a more attractive launch market could help reduce the number of terminated technology appraisals conducted by NICE, the health technology appraisal institute, says the UK pharmaceutical industry.

Non-Submissions To England’s NICE Surge Across All Disease Areas

 
• By 

Blood cancer therapies were most proportionately impacted by the failure of pharmaceutical companies to submit evidence on their cancer therapies to England’s health technology appraisal body, shows analysis by the Pink Sheet.

PBMs No Longer Profit From Rebates But Plans Benefit; Should Sponsors Push More For Reform?

 
• By 

Employers and other health plan sponsors may need to push for better targeted reforms that lower cost sharing for patients.